Pompe disease or Glycogen Storage Disease is a rare genetic disease caused by the buildup of a sugar called glycogen in the body’s cells. The accumulation of glycogen in cells, especially in the muscles, including the heart muscle, affects normal function. The heart and skeletal muscles are most affected in Pompe disease. The disease is caused by genetic mutations that lead to deficiency or absence of the enzyme acid alpha-glucosidase (GAA), also known as acid maltase. This enzyme is required to breakdown glycogen, a stored sugar into glucose. Pompe disease exists in three forms-infantile, juvenile, and adult-onset. Heart problems, muscle weakness, and breathing problems may occur in children suffering Pompe disease.
The often fatal disease is diagnosed by testing for the specific gene mutations, using blood tests to check the levels of GAA, or with a muscle biopsy. Treatment modalities include enzyme replacement using alglucosidase alfa (Myozyme) are available.
What are the Causes of Pompe Disease?
Glycogen is a stored form of sugar. The enzyme GAA is used to breakdown glycogen into a simpler sugar, glucose. The process happens inside intracellular compartments called lysosomes. Mutations in the GAA gene (the gene that is responsible for producing GAA) lead to the reduction or complete absence of this enzyme. Up to 300 different mutations in the GAA genes have been found to be associated with Pompe disease.
The enzyme deficiency or absence leads to excessive accumulation of lysosomal glycogen everywhere in the body. The cells of the heart and skeletal muscles are affected the most.
Pompe disease is also referred to as Glycogen-storage disease type II (GSDII). It is an autosomal recessive disorder, i.e. each parent of an affected individual must pass on a copy of the mutated gene so that the child gets the disease. Pompe disease is relatively rare; it affects one in 40,000 people.
Latest Publications and Research on Pompe DiseasePhase I/II trial of AAV1-GAA gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. - Published by PubMed
[Metabolic and mitochondrial myopathies]. - Published by PubMed
Receiving Enzyme Replacement Therapy for a Lysosomal Storage Disorder: A Preliminary Exploration of the Experiences of Young Patients and Their Families. - Published by PubMed
Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. - Published by PubMed
Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to an Adeno-Associated Virus Vector in Murine Pompe Disease. - Published by PubMed